Ophthalmology Product Company Graybug Vision to Present Data at ARVO 2016


Redwood City, CA – April 25, 2016 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that data from its preclinical research will be highlighted in presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting, taking place May 1 to 5 in Seattle, WA.

Graybug Vision has two products in preclinical development for the treatment of ocular diseases.  Its lead product, GB-102, is a novel injectable depot formulation containing a compound blocking VEGF and PDGF receptors for twice a year treatment of wet AMD.

On May 2nd, Peter A. Campochiaro, MD, Director, Retinal Cell and Molecular Laboratory at Johns Hopkins University Wilmer Eye Institute, will present data from a murine study of GB-102 in a poster entitled “Sustained Suppression of Murine Choroidal Neovascularization by Intravitreous Injection of Sunitinib-encapsulated Polymer Microparticles.”

On May 4th, Graybug Vision researchers Ming Yang, PhD, and Ward M. Peterson, PhD, will present data from an in vivo toxicology/PK study of GB-102 in a poster entitled “GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months.”

Details of the poster presentations are as follows:

  • Title: Sustained Suppression of Murine Choroidal Neovascularization by Intravitreous Injection of Sunitinib-encapsulated Polymer Microparticles
    Poster Number: 2147 – C0054
  • Session Title: AMD and CNV: Clinical and Translational
  • Date: Monday, May 2, 2016
  • Time: 11:00 AM to 12:45 PM
  • Title: GB-102 for Wet AMD: A Novel Injectable Formulation that Safely Delivers Active Levels of Sunitinib to the Retina and RPE/Choroid for Over Four Months
  • Poster Number: 5037 – B0243
  • Session Title: Anti-VEGF
  • Date: Wednesday, May 4, 2016
  • Time: 11:00 AM to 12:45 PM

About Graybug Vision

Graybug Vision is developing novel products for the treatment of ocular diseases.  Graybug Vision’s technologies enable the delivery of compounds to the eye up to twice per year and were co-developed by Graybug Vision founder Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with Graybug Vision cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD.  Graybug Vision’s lead product, GB-102, is being developed for twice a year treatment of wet AMD patients.  Graybug Vision’s second product consists of compounds with intraocular pressure lowering and neuroprotection that may be administered to the subconjunctiva twice per year for the treatment of glaucoma.  For more information, please visit www.graybug.com.

Related News

Press release

Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis

Redwood City, CA – February 5, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative therapies for ocular diseases, today announced that the Board of Directors has appointed Frédéric Guerard as Read more…

Press release

Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019

ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) • Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF Read more…

Press release

Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual Meeting

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Graybug Vision, Inc., a clinical stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening ocular diseases including wet age-related macular degeneration (wet AMD) and primary open angle glaucoma (POAG), today Read more…